XWARNNG
Market cap21mUSD
Dec 23, Last price
2.78PLN
1D
1.46%
1Q
-27.42%
IPO
-34.59%
Name
Nanogroup SA
Chart & Performance
P/E
—
P/S
43,553.06
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.05%
Rev. gr., 5y
-55.07%
Revenues
2k
-98.55%
Net income
-8m
L+922.61%
CFO
-5m
L+29.20%
Profile
NanoGroup S.A. operates as a biotechnology company. It develops and licenses early-stage biotechnology and medical projects in the areas of oncology, transplantology, and blood donations to international biotech companies and pharmaceutical companies. NanoGroup S.A was incorporated in 2016 and is based in Warsaw, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑10 | 2015‑10 | 2014‑12 | |
| Income | |||||||||||
Revenues | 2 -98.55% | 140 -71.66% | 492 -28.37% | ||||||||
Cost of revenue | 13,338 | 1,295 | 7,021 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (13,336) | (1,156) | (6,529) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | (12) | ||||||||||
Tax Rate | |||||||||||
NOPAT | (13,336) | (1,144) | (6,529) | ||||||||
Net income | (7,890) 922.61% | (772) | |||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 5,911 | 3,350 | 1,000 | ||||||||
BB yield | -31.69% | -16.08% | 0.00% | ||||||||
| Debt | |||||||||||
Debt current | 139 | 146 | |||||||||
Long-term debt | 139 | 424 | |||||||||
Deferred revenue | 9,992 | 7,290 | |||||||||
Other long-term liabilities | |||||||||||
Net debt | (538) | (2,231) | (3,431) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (4,761) | (3,685) | |||||||||
CAPEX | (76) | (807) | |||||||||
Cash from investing activities | (3,657) | (807) | |||||||||
Cash from financing activities | 6,485 | 2,963 | 748 | ||||||||
FCF | (12,939) | (823) | (6,057) | ||||||||
| Balance | |||||||||||
Cash | 538 | 2,471 | 3,999 | ||||||||
Long term investments | 38 | 2 | |||||||||
Excess cash | 538 | 2,502 | 3,977 | ||||||||
Stockholders' equity | (29,829) | (12,873) | 17,380 | ||||||||
Invested Capital | 34,988 | 30,632 | 11,843 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 20,097 | 16,748 | 16,748 | ||||||||
Price | 0.93 -25.40% | 1.24 -65.35% | 3.59 -18.04% | ||||||||
Market cap | 18,650 -10.48% | 20,834 -65.35% | 60,125 -18.04% | ||||||||
EV | 18,795 | 27,997 | 69,459 | ||||||||
EBITDA | (13,301) | (1,094) | (6,464) | ||||||||
EV/EBITDA | |||||||||||
Interest | 515 | 1 | |||||||||
Interest/NOPBT | |||||||||||